WebJan 10, 2024 · GB0139. inhaled galectin-3 inhibitor. Ph. II for IPF + Ph. Ib/IIa for COVID-19 pneumonitis. synthetic galactoside derivative. medRxiv, January 10, 2024. Galecto, Inc., … WebGB0139, an inhaled small molecule inhibitor of galectin-3, a protein known to play a central role in fibrosis in several organs, has received Orphan Drug Designation (ODD) from both the US FDA and the EMA for the treatment of IPF.

Galecto IPF Phase IIb trial goes full steam ahead

WebMar 7, 2024 · GB0139 was administered as an inhaled formulation of 10 mg twice daily via a dry powder inhaler (Plastiape; Berry Bramlage) for the first 48 hours, followed by 10 mg once daily for up to 14 days or until discharge from the hospital or withdrawal from the trial. WebNov 30, 2024 · GB0139 was shown to be safe and well tolerated in healthy subjects and IPF patients in the phase 2a trial, and dose dependently suppressed expression of galectin-3, a protein known to play a ... closing inbound before receiving peer\u0027s

80+ Active Companies working to develop 80+ Pipeline

WebFeb 4, 2024 · Detailed Description. This study is designed to evaluate the efficacy and safety of GB0139, a galectin-3 inhibitor, administered by dry powder inhalation over 52 weeks. … WebThe Current Procedural Terminology (CPT ®) code 20939 as maintained by American Medical Association, is a medical procedural code under the range - General Grafts (or … WebGB0139 (formerly TD139) is a galectin-3 inhibitor administered by dry powder inhalation. Study Purpose. This is a randomized, double-blind, placebo-controlled phase 2b trial in … closing in bottom of deck